Skip directly to site content Skip directly to search


Español  Other Languages


An official website of the United States government Here's how you know
 Official icon**Official websites use .gov**
				A .gov website belongs to an official government organization in the United States. Lock icon**Secure .gov websites use HTTPS**
				A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
	CDC LogoCDC Logo
 Search

		×
			NIOSH
			NIOSH

				All CDC
				Submit


The National Institute for Occupational Safety and Health (NIOSH)





Current Intelligence Bulletin 16: Metabolic Precursors Beta-Naphthylamine						Print
																Related Pages
										December 17, 1976
DHHS (NIOSH) Publication Number 78-127
The National Institute for Occupational Safety and Health (NIOSH) has recently learned that both N-phenyl-*B*-naphthylamine (a widely used rubber antioxidant) and 2-nitronaphthalene (a by-product of a-naph-thylamine production) are metabolized to the known human carcinogen, *B*-naphthylamine. This Bulletin emphasizes the potential problem of the metabolic conversion of materials believed to be relatively innocuous into known human carcinogens.

Phenyl-Beta-Naphthylamine
In an October 8, 1976 letter to NIOSH, The B. F. Goodrich Company reported findings indicating that phenyl-*B*-naphthylamine (PBNA) is metabolized to *B*-naphthylamine (BNA) by the human body. This confirms an earlier study by Shell Nederland (T. Soc. Geneesk., 53: 415-19, 1975).
PBNA was developed as a replacement chemical for BNA when, in the late 1940’s, an association was shown to exist between BNA and human bladder cancer. It should be noted, however, that commercial PBNA is contaminated with 20-30 parts per million BNA.
In recent years, there have been three major domestic manufacturers of PBNA. E. I. du Pont de Nemours and Company manufactured PBNA at Deepwater, New Jersey, until December 1975. The only known current domestic producers of PBNA are the B. F. Goodrich Company at Akron, Ohio and Uniroyal, Inc., at Naugatuck, Connecticut. Total domestic production of PBNA was 4.9 million pounds in 1973, 3 million in 1974, and 1.5 million in 1975.
Most of the phenyl-*B*-naphthylamine manufactured today is used as an antioxidant in rubber where it can comprise as much as 1% of the finished product. It can also find use as an antioxidant for greases and oils, as a stabilizer during the manufacture of synthetic rubber, and as an intermediate in the synthesis of dyes as well as other antioxidants. NIOSH estimates that 15,000 workers are potentially exposed to PBNA during its manufacture and use. The majority of these exposures are found among rubber fabricators.
Due to the wide use of PBNA in the rubber industry and its structural similarity to BNA, Shell Nederland studied the metabolism of PBNA. This study included four process operators with occupational exposure (by inhalation) to PBNA, along with 19 volunteers who each ingested 10 mg PBNA. Subsequently, one of these volunteers ingested an additional 30 mg PBNA. BNA measured in 24-hour urine samples was in excess of the quantity that would be expected as an impurity of the ingested PBNA. For the volunteers who consumed 10 mg PBNA (contaminated with 0.008μg BNA), 0.4 to 3μg BNA was found in their urine. The process operators, estimated to have inhaled 40 mg PBNA (contaminated with 0.032μg BNA), were found to have 3 to 8 BNA in their urine samples.
As a confirmation of Shell’s findings, B. F. Goodrich found 3 to 4μg BNA in 24-hour urine samples from two volunteers who ingested 50 mg PBNA (containing 0.7μg BNA) and from workers (unspecified number) estimated to have inhaled 30 mg PBNA. These findings, like the Shell study, indicate that phenyl-*B*-naphthylamine is at least partially metabolized by the human body to *B*-naphthylamine.
The acute and chronic toxicity of PBNA has been demonstrated in laboratory animals, however, its toxic effects in man are virtually unknown. An epidemiologic study, involving deaths among workers who entered the rubber industry after 1949 (when BNA was replaced by PBNA), shows no significant excess risk of bladder tumors in the industry when compared to the general population. The authors point out, however, that their data is not conclusive (Brit.J.Ind.Med., 31: 140-51, 1974).
In addition to the studies demonstrating that PBNA is metabolized to BNA in humans, evidence has been presented which indicates that PBNA is also metabolized to BNA in dogs. At the Imperial Chemical Industries Laboratory in Manchester, England, radioactive PBNA was fed to dogs and radioactive BNA was found in collected urine.
The carcinogenic potential of PBNA in laboratory animals has undergone limited evaluation. In a study involving three female dogs (fed 540 mg PBNA per day over a period of years), no bladder tumors were seen after 4.5 years. The investigators point out that the relatively few years of exposure to PBNA limits interpretation of these data (Proc. 9th Int. Cong. Ind. Med., Budapest, 1948).
In a limited number of laboratory mice fed PBNA for 18 months, the incidence of hepatomas, when compared with controls, was significantly greater than expected. Other laboratory mice, given a single subcutaneous injection of PBNA, showed an increase in the total number of tumors when compared with controls; however, in this group, the incidence of site-specific tumors was not significantly greater than expected (National Cancer Institute, Aug. 1968).

2-Nitronaphthalene
On August 19, 1976, E. I. du Pont de Nemours and Company informed NIOSH of unpublished studies regarding the carcinogenic potential and the metabolism of 2-nitronaphthalene in dogs. This compound (an unmarketed by-product produced during the commercial preparation of a-naphthylamine), like PBNA, is metabolized in laboratory dogs to BNA.
In a study by DuPont, 2-nitronaphthalene was fed (100 mg/kg and 50 mg/kg) to a female Beagle dog and *B*-naphthylamine was found in the urine. In another study (conducted by Allied Chemical), four female dogs were fed 100 mg of 2-nitronaphthalene daily for 8 months. After 10.5 years, bladder papillomas were observed in various stages of malignancy in the 3 dogs for which autopsy results were available. Allied concluded from this study that 2-nitronaphthalene is an active carcinogen in the female dog. In addition, 2-nitronaphthalene has been shown to be metabolized in monkeys to BNA (JNCI, 50: 989-95, 1973). However, there are no reports concerning the metabolic fate of 2-nitronaphthalene in man.

Recommendations
The fact that certain substances, as illustrated by PBNA and 2-nitronaphthalene, can be metabolized to known carcinogens, lends a new perspective to controlling workplace hazards. NIOSH therefore recommends that:
Industrial hygiene practices should be followed to minimize exposure to phenyl-*B*-naphthylamine in the workplace  (attached).
Although there are a number of antioxidants which may be substituted for phenyl-*B*-naphthylamine, alternatives should be fully evaluated with regard to possible human effects.
More consideration should be given to the assessment of metabolic pathways of chemical agents found in the workplace.
Materials which can be metabolized by the human body to known carcinogens should be handled in the same manner as carcinogens.The National Institute for Occupational Safety and Health is making recommendations to the Occupatitional Safety and Health Administration (OSHA) for regulatory action.
*[signature]*
John F. Finklea, M.D.
Director

Industrial Hygiene Practices to Minimize Exposure to Phenyl-B-Naphthylamine
The recent confirmation of *B*-naphthylamine as a metabolic by-product, as well as a contaminant of phenyl-*B*-naphthylamine (PBNA) has indicated the need for minimizing exposure to PBNA. The following are suggested good industrial hygiene practices.
**Regulated Area:** Regulated areas should be established where PBNA is manufactured, processed, used, repackaged, released, handled or stored.
**Access.** Access should be restricted to employees who have been properly informed of the potential hazard of PBNA exposure and proper control methods.
**Engineering Controls.** most effective control of any potentially toxic substance is control at the source of generation. Effective engineering measures include the use of walk-in hoods or specific local exhaust ventilation with suitable collectors.
**Respirators.** Personal respiratory protective devices should only be used as an interim measure while engineering controls are being installed, for non-routine use and during emergencies. Considering the carcinogenic potential and the lack of a standard, the appropriate personal respiratory protective measure is the use of a positive pressure supplied air respirator or a positive pressure self-contained breathing apparatus.
**Protective Clothing.** Protective full body clothing should be provided and its use required for employees enterinq the regulated area. Upon exiting from the regulated area, the protective clothing should be left at the point of exit. With the last exit of the day, the protective clothing should be placed in a suitably marked and closed container for disposal or laundering. (Laundry personnel should be made aware of the potential hazard from handling contaminated clothing.)
**Personal Cleanliness.** should be required to wash all exposed areas of the body upon exiting from the regulated area.
**Empty Containers.** PBNA containers should be placed in impervious bags to reduce possible contamination. These containers should be disposed of in a safe manner.**Medical Monitoring:** All emoloyees with a potential exposure to PBNA should be placed under a medical monitoring program including history and medical examinations to detect the presence of bladder cancers and specific urine analysis for *B*-naphthylamine.
**Substitution:** The substitution of another antioxidant for PBNA is a possible control measure. However, alternatives to PBNA should be fully evaluated with reqard to possible human effects. [return to text]
							
					
							Last Reviewed:  June 6, 2014						Source: 	National Institute for Occupational Safety and Health
					Facebook
        Twitter
        LinkedIn
        Syndicate homeNIOSH Publications & Products
NIOSH-Issued Publications
Search NIOSHTIC-2 Research Database
Docket
Documents for Public Review
Peer Review Agenda
Databases
eNews
Federal Register Noticesplus icon
FRN Archive 2007-2010
FRN Archive 2005-2006
FRN Archive 2001-2004
FRN Archive 1996-2000
Press Releases and Updatesplus icon
Press Release Archives 2010-2013
Press Release Archives 2006-2009
Press Release Archives 2001-2005
Press Release Archives 1998-2000
Press Release Archives 1992-1997
Regulations
Regulatory Agenda
Science Blog
Software
Video Error processing SSI file  Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue